Incyte Corporation provided revenue guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million. The company expects other Hematology/Oncology net product revenues of $325 million - $360 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.35 USD | -0.30% | +0.36% | -15.15% |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
05-01 | TD Cowen Adjusts Price Target on Incyte to $80 From $88 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.15% | 12.02B | |
-3.35% | 88.91B | |
+2.76% | 41.25B | |
-14.30% | 31.99B | |
+50.51% | 24.73B | |
-15.08% | 15.54B | |
-39.93% | 12.07B | |
-9.08% | 12.05B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Provides Revenue Guidance for 2024